{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:28:02Z","timestamp":1751966882383,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Key Research and Development Plan of Hubei Province","award":["2023BCB030"],"award-info":[{"award-number":["2023BCB030"]}]},{"DOI":"10.13039\/501100004433","name":"Chinese Pharmaceutical Association","doi-asserted-by":"publisher","award":["CPA-Z05-ZC-2022-002"],"award-info":[{"award-number":["CPA-Z05-ZC-2022-002"]}],"id":[{"id":"10.13039\/501100004433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40261-024-01359-x","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T18:02:12Z","timestamp":1713031332000},"page":"343-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic Interactions Between Tegoprazan and the Combination of Clarithromycin, Amoxicillin and Bismuth in Healthy Chinese Subjects: An Open-Label, Single-Center, Multiple-Dosage, Self-Controlled, Phase I Trial"],"prefix":"10.1007","volume":"44","author":[{"given":"Yujing","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junrui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejia","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7172-9913","authenticated-orcid":false,"given":"Yongning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420\u20139.","journal-title":"Gastroenterology"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11938-020-00300-3","volume":"18","author":"N Saleem","year":"2020","unstructured":"Saleem N, Howden CW. Update on the management of helicobacter pylori infection. Curr Treat Options Gastroenterol. 2020;18:476\u201387.","journal-title":"Curr Treat Options Gastroenterol."},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"175628482198917","DOI":"10.1177\/1756284821989177","volume":"14","author":"C Liu","year":"2021","unstructured":"Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, et al. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Ther Adv Gastroenterol. 2021;14:1756284821989177.","journal-title":"Ther Adv Gastroenterol"},{"key":"1359_CR4","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","volume":"155","author":"A Savoldi","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155:1372-1382.e17.","journal-title":"Gastroenterology"},{"key":"1359_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12714","volume":"25","author":"Y Zou","year":"2020","unstructured":"Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter. 2020;25: e12714.","journal-title":"Helicobacter"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/hel.12299","volume":"21","author":"Y Hu","year":"2016","unstructured":"Hu Y, Zhang M, Lu B, Dai J. Helicobacter pylori and antibiotic resistance a continuing and intractable problem. Helicobacter. 2016;21:349\u201363.","journal-title":"Helicobacter"},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/CM9.0000000000000618","volume":"133","author":"Y Hu","year":"2020","unstructured":"Hu Y, Zhu Y, Lu N-H. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335\u201343.","journal-title":"Chin Med J (Engl)"},{"key":"1359_CR8","doi-asserted-by":"publisher","first-page":"1257817","DOI":"10.3389\/fcimb.2023.1257817","volume":"13","author":"Q Sun","year":"2023","unstructured":"Sun Q, Yuan C, Zhou S, Lu J, Zeng M, Cai X, et al. Helicobacter pylori infection: a dynamic process from diagnosis to treatment. Front Cell Infect Microbiol. 2023;13:1257817.","journal-title":"Front Cell Infect Microbiol"},{"key":"1359_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23: e12475.","journal-title":"Helicobacter"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","volume":"12","author":"M Sugimoto","year":"2007","unstructured":"Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12:317\u201323.","journal-title":"Helicobacter"},{"key":"1359_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12768","volume":"26","author":"H Ke","year":"2021","unstructured":"Ke H, Li J, Lu B, Yang C, Wang J, Wang Z, et al. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy. Helicobacter. 2021;26: e12768.","journal-title":"Helicobacter"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/00042737-199911000-00016","volume":"11","author":"HG Dammann","year":"1999","unstructured":"Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol. 1999;11:1277\u201382.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/nyas.14473","volume":"1482","author":"C Scarpignato","year":"2020","unstructured":"Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, et al. Pharmacologic treatment of GERD: where we are now, and where are we going? Ann N Y Acad Sci. 2020;1482:193\u2013212.","journal-title":"Ann N Y Acad Sci"},{"key":"1359_CR14","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1185\/03007990903035745","volume":"25","author":"WD Chey","year":"2009","unstructured":"Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009;25:1869\u201378.","journal-title":"Curr Med Res Opin"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1067\/mcp.2001.113959","volume":"69","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69:158\u201368.","journal-title":"Clin Pharmacol Ther"},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.amjcard.2010.01.348","volume":"105","author":"C-C Huang","year":"2010","unstructured":"Huang C-C, Chen Y-C, Leu H-B, Chen T-J, Lin S-J, Chan W-L, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010;105:1705\u20139.","journal-title":"Am J Cardiol"},{"key":"1359_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.12793\/tcp.2023.31.e11","volume":"31","author":"M Oh","year":"2023","unstructured":"Oh M, Lee H, Kim S, Kim B, Song GS, Shin J-G, et al. Evaluation of pharmacokinetic drug\u2013drug interaction between tegoprazan and clarithromycin in healthy subjects. Transl Clin Pharmacol. 2023;31:114\u201323.","journal-title":"Transl Clin Pharmacol."},{"key":"1359_CR18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5056\/jnm18029","volume":"24","author":"T Oshima","year":"2018","unstructured":"Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24:334\u201344.","journal-title":"J Neurogastroenterol Motil."},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5009\/gnl20247","volume":"15","author":"JW Lee","year":"2021","unstructured":"Lee JW, Kim N, Nam RH, Yu JE, Son JH, Lee SM, et al. Efficacy of tegoprazan for improving the susceptibility of antimicrobial agents against antibiotic-resistant Helicobacter pylori. Gut Liver. 2021;15:53\u201360.","journal-title":"Gut Liver."},{"key":"1359_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12977","volume":"28","author":"JS Kim","year":"2023","unstructured":"Kim JS, Ko W, Chung J-W, Kim TH. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: a randomized, double-blind, active-controlled study. Helicobacter. 2023;28: e12977.","journal-title":"Helicobacter"},{"key":"1359_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3349\/ymj.2021.62.8.708","volume":"62","author":"JY Kim","year":"2021","unstructured":"Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. Efficacy of seven-day potassium-competitive acid blocker-based first-line Helicobacter pylori eradication therapy administered with bismuth. Yonsei Med J. 2021;62:708\u201316.","journal-title":"Yonsei Med J"},{"key":"1359_CR22","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000632","volume":"14","author":"CH Park","year":"2023","unstructured":"Park CH, Park JH, Jung YS. Comparative efficacy of tegoprazan vs esomeprazole\/sodium bicarbonate for the treatment of Helicobacter pylori infection. Clin Transl Gastroenterol. 2023;14: e00632.","journal-title":"Clin Transl Gastroenterol"},{"key":"1359_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.5009\/gnl220218","volume":"17","author":"YS Jung","year":"2023","unstructured":"Jung YS, Kim S, Kim H-Y, Noh SJ, Park JH, Sohn CI, et al. Efficacy and tolerability of 14-day tegoprazan- versus rabeprazole-based triple therapy for eradication of Helicobacter pylori: a real-world evidence study. Gut Liver. 2023;17:711\u201321.","journal-title":"Gut Liver."},{"key":"1359_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.5009\/gnl220055","volume":"16","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Lee YC, Kim JM, Kim JI, Moon JS, Lim YJ, et al. Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase III, clinical trial. Gut Liver. 2022;16:535\u201346.","journal-title":"Gut Liver."},{"key":"1359_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.clinthera.2021.01.026","volume":"43","author":"J-Y Jeon","year":"2021","unstructured":"Jeon J-Y, Kim S-Y, Moon SJ, Oh K, Lee J, Kim B, et al. Pharmacokinetic interactions between tegoprazan and metronidazole\/tetracycline\/bismuth and safety assessment in healthy Korean male subjects. Clin Ther. 2021;43:722\u201334.","journal-title":"Clin Ther"},{"key":"1359_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/cts.12958","volume":"14","author":"DY Yoon","year":"2021","unstructured":"Yoon DY, Sunwoo J, Shin N, Kim AR, Kim B, Song GS, et al. Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers. Clin Transl Sci. 2021;14:934\u201341.","journal-title":"Clin Transl Sci"},{"key":"1359_CR27","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/S1734-1140(12)70953-2","volume":"64","author":"E Sza\u0142ek","year":"2012","unstructured":"Sza\u0142ek E, Karbownik A, Po\u0142om W, Matuszewski M, Soba\u0144ska K, Urjasz H, et al. Sunitinib in combination with clarithromycin or azithromycin: is there a risk of interaction or not? Pharmacol Rep PR. 2012;64:1554\u20139.","journal-title":"Pharmacol Rep PR."},{"issue":"11","key":"1359_CR28","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1016\/j.xphs.2021.06.011","volume":"110","author":"DD Thambavita","year":"2021","unstructured":"Thambavita DD, Galappatthy P, Jayakody RL. Pharmacokinetics and bioequivalence of two amoxicillin 500 mg products: effect of food on absorption and supporting scientific justification for biowaiver. J Pharm Sci. 2021;110(11):3735\u201341.","journal-title":"J Pharm Sci"},{"key":"1359_CR29","first-page":"588","volume":"54","author":"R Koytchev","year":"2004","unstructured":"Koytchev R, Ozalp Y, Erenmemisoglu A, van der Meer MJ, Alpan RS. Studies on the bioequivalence of different strengths of tablets containing clarithromycin. Arzneimittelforschung. 2004;54:588\u201393.","journal-title":"Arzneimittelforschung"},{"key":"1359_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.12793\/tcp.2019.27.2.80","volume":"27","author":"JG Hwang","year":"2019","unstructured":"Hwang JG, Yoo H, Lee JW, Song GS, Lee S, Kim M-G. Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects. Transl Clin Pharmacol. 2019;27:80\u20135.","journal-title":"Transl Clin Pharmacol."},{"key":"1359_CR31","doi-asserted-by":"publisher","first-page":"12767","DOI":"10.3748\/wjg.v20.i36.12767","volume":"20","author":"S Alzahrani","year":"2014","unstructured":"Alzahrani S, Lina TT, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Effect of Helicobacter pylori on gastric epithelial cells. World J Gastroenterol. 2014;20:12767\u201380.","journal-title":"World J Gastroenterol"},{"key":"1359_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","volume":"12","author":"DY Graham","year":"2007","unstructured":"Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275\u20138.","journal-title":"Helicobacter"},{"key":"1359_CR33","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/mnfr.200700081","volume":"52","author":"BJ Gurley","year":"2008","unstructured":"Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John\u2019s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52:772\u20139.","journal-title":"Mol Nutr Food Res"},{"key":"1359_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2131\/jts.41.143","volume":"41","author":"T Niwa","year":"2016","unstructured":"Niwa T, Morimoto M, Hirai T, Hata T, Hayashi M, Imagawa Y. Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016;41:143\u20136.","journal-title":"J Toxicol Sci"},{"key":"1359_CR35","first-page":"124","volume":"57","author":"F Yamamoto","year":"2004","unstructured":"Yamamoto F, Harada S, Mitsuyama T, Harada Y, Kitahara Y, Yoshida M, et al. Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin. Jpn J Antibiot. 2004;57:124\u201333.","journal-title":"Jpn J Antibiot"},{"key":"1359_CR36","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/jac\/34.6.1025","volume":"34","author":"G Cederbrant","year":"1994","unstructured":"Cederbrant G, Kahlmeter G, Schal\u00e9n C, Kamme C. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother. 1994;34:1025\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1359_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jpba.2011.01.019","volume":"55","author":"S Oswald","year":"2011","unstructured":"Oswald S, Peters J, Venner M, Siegmund W. LC-MS\/MS method for the simultaneous determination of clarithromycin, rifampicin and their main metabolites in horse plasma, epithelial lining fluid and broncho-alveolar cells. J Pharm Biomed Anal. 2011;55:194\u2013201.","journal-title":"J Pharm Biomed Anal"},{"key":"1359_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.12793\/tcp.2020.28.e5","volume":"28","author":"WY Lee","year":"2020","unstructured":"Lee WY, Oh E, Cui M, Kim CO, Lim Y, Kim H, et al. Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects. Transl Clin Pharmacol. 2020;28:55\u201365.","journal-title":"Transl Clin Pharmacol."},{"key":"1359_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/clpt.1994.61","volume":"55","author":"G Treiber","year":"1994","unstructured":"Treiber G, Walker S, Klotz U. Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. Clin Pharmacol Ther. 1994;55:486\u201391.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01359-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:34:27Z","timestamp":1715405667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01359-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01359-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"26 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Key Research and Development Plan of Hubei Province, China (2023BCB030) and the Chinese Pharmaceutical Association (CPA-Z05-ZC-2022-002). The study was also supported by Shandong Luoxin Pharmaceutical Group Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Liangwei Song, Fang Xie, Yinghui Wang, Yuhao Chen, and Chengxin Liu are employees of Shandong Luoxin Pharmaceutical Group Co., Ltd. They have no other relevant disclosures to declare. Yujing Du, Lixiu Yu, Bin Deng, Qinying Li, Junrui Hu, Linjie Li, Yusen Xu, Xuejia Zhai, and Yongning Lu have no relevant conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data presented in this study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The study was approved by the Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology [approval no. (2022) 0945] on 10 January 2023. The study was performed in accordance with the Good Clinical Practice standards of China National Medical Products Administration, the current Declaration of Helsinki (as revised in 2013), and relevant regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Conceptualization: All authors. Methodology: BD, QL, JH. Formal analysis and investigation: LL, YX. Writing \u2013 original draft preparation: YD. Writing \u2013 review and editing: LY, YW, YC, CL, XZ, YL. Funding acquisition: XZ, YL. Resources: LS, FX. Supervision: XZ, YL. Project administration: YL. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}